Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms by Site × ribociclib × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3 Head & Neck 1 Gynecologic 1 Endocrine 1

Conditions

Multiple Endocrine Neoplasia Type 1 2 Breast Neoplasms 2 Neuroendocrine Tumors 1 Neoplasms by Site 1 Neoplasms 1 Breast Diseases 1

Interventions

selpercatinib 2 trametinib 1 ribociclib 1 repotrectinib 1 pralsetinib 1 lutetium Lu 177 dotatate 1 dabrafenib 1 copper dotatate CU-64 1 cobimetinib 1 alectinib 1 Vemurafenib 1 Sunitinib 1 Lutetium-177 1 Lutetium 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02422615 2023-11-30

MONALEESA-3

Novartis

Phase 3 Completed

726 enrolled 17 charts 1 FDA

BreastEndocrine

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡